Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

A. Armuzzi, Paolo Gionchetti, Marco Daperno, Silvio Danese, Ambrogio Orlando, Maria Lia Scribano, Maurizio Vecchi, Fernando Rizzello, S. Ardizzone, Fabiana Castiglione, Massimo Claudio Fantini, Gionata Fiorino, G. Frieri, L. Neri, M. L. Scribano, G. C. Sturniolo

Research output: Contribution to journalArticle

Abstract

Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic, relapsing conditions resulting from uncontrolled inflammation of the intestinal mucosa. Both conditions are associated with significant disability and patients with CD face higher mortality rates compared to the general population. The increasing understanding of the immunological basis of the disease led to the introduction of biologic therapies targeting key pathways of the natural and adaptive immune response such as Tumor Necrosis Factor α (TNF-α) inhibitors and, more recently, integrin-receptor antagonists. Treatment with TNF-α inhibitors improved clinical and patient-reported outcomes for many patients who did not benefit from conventional therapy. However, a sizeable share of patients still face suboptimal outcomes due to primary or secondary therapy failure. With the introduction of VDZ, a biologic treatment targeting novel IBD-relevant biologic pathways, it is crucial to understand how to integrate such innovations into current clinical practice. To this end, a panel of 14 Italian experts in the management of IBD met for a roundtable discussion. Recommendations concerning the management of moderate-to-severe IBD based on experts' opinions and literature review are discussed in the present report.

Original languageEnglish
Pages (from-to)360-370
Number of pages11
JournalDigestive and Liver Disease
Volume48
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Keywords

  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Vedolizumab

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease'. Together they form a unique fingerprint.

  • Cite this

    Armuzzi, A., Gionchetti, P., Daperno, M., Danese, S., Orlando, A., Lia Scribano, M., Vecchi, M., Rizzello, F., Ardizzone, S., Castiglione, F., Fantini, M. C., Fiorino, G., Frieri, G., Neri, L., Scribano, M. L., & Sturniolo, G. C. (2016). Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 48(4), 360-370. https://doi.org/10.1016/j.dld.2015.12.016